Sanofi wins FDA TB nod; UCB brings on Daiichi to market Vimpat in Japan;

> Sanofi ($SNY) has won FDA approval for Priftin tablets to treat latent tuberculosis infection. Release (PDF)

> Daiichi Sankyo has teamed up with UCB to commercialize epilepsy treatment Vimpat in Japan. Report

> Ranbaxy and Epirus have launched a biosimilar of Johnson & Johnson's ($JNJ) Remicade in India. More

> The EU has greenlighted Astellas' Xtandi for prechemo prostate cancer. Report

> Otsuka says new pickup Avanir's ($AVNR) sales and marketing capabilities can help it create a global CNS company. Release

And Finally... GlaxoSmithKline ($GSK) has named the winners for its drug-hunter challenge. More

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.